Navigation Links
DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
Date:6/22/2013

New York, NY (PRWEB) June 22, 2013

The diabetes drug safety advocates at DrugRisk.com are announcing new information on the site for those patients taking the medications Januvia or Janumet. A federal panel will meet next week to decide which court venue will handle growing lawsuits alleging the drugs caused cancer*.

The goal of DrugRisk is to improve the safety of patients taking popular prescription drugs like Januvia and Janumet by providing the latest warnings, recalls, studies and legal news. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.

Januvia and Janumet are pill-form diabetes medications prescribed to help those with type-2 diabetes control blood sugar. The drugs were two of the best-selling for Merck in recent years, with sales of over $4 billion last year**.

The resource center contains studies suggesting Januvia and Janumet may be linked to cancer. A 2011 study from UCLA indicated the drug could increase the risk of pancreatic cancer by 172% and thyroid cancer by 48%***. The FDA is also investigating the risk of Janumet and Januvia cancer after receiving reports that some patients who died showed signs of early pancreatic cancer cells****.

DrugRisk also added a report by Dr. Peter Butler, head of endocrinology at UCLA, warning that the Januvia pancreatic cancer risk was not detected in trials prior to FDA approval because the manufacturer used very young animals not as prone to pancreatic cancer*****.

Now, with 53 patients having already filed a Januvia lawsuit alleging cancer, the Judicial Panel on Multidistrict Litigation will meet on July 25th to determine where to consolidate the growing number of cases*. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).

Anyone affected by cancer after taking Januvia or Janumet is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Januvia lawsuits.

For more information on the research, side effects and litigation news related to Januvia and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*JPML, 6/12/13; jpml.uscourts.gov/sites/jpml/files/Hearing_Order-7-25-13.pdf
**Bloomberg, 2/25/13; bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
***Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
****FDA, 3/14/13; http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm
*****New York Times, 5/31/13; nytimes.com/2013/05/31/business/a-doctor-raises-questions-about-a-diabetes-drug.html?hp&_r=1&

Read the full story at http://www.prweb.com/releases/januvia-lawsuit/pancreatic-thyroid-cancer/prweb10859222.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
2. DrugRisk Announces Alternative to Mirena IUD May Be Available Soon
3. DrugRisk Announces Updated Information on Mirena Lawsuits
4. DrugRisk Adds Latest Health Warnings and Lawsuit Updates for Yaz
5. DrugRisk Announces New Pradaxa Health Warning From Australia
6. DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year
7. DrugRisk Update: Court Allows Charges of Prior Fraud Into Pradaxa Lawsuit
8. DrugRisk Pradaxa Lawsuit Update: Court Denys Boehringer’s Protective Order Request
9. DrugRisk Pradaxa Update: Litigation Grows As New Study Adds to Risks
10. DrugRisk Update: Bayer Discloses $500 Million Remaining for Yaz Lawsuits
11. DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... August 18, 2017 , ... Paragon and ... to help the cannabis industry move towards greater legitimacy. By incorporating IOTA’s unique ... technology with lower fees. Paragon will build a fully verifiable database to track ...
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... Yesterday, the ... KKK by saying there are two sides. There are not two sides to hatred, ... to rationalize violence and prejudice, and the NPEIV stands against all forms of such ...
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of shoes made their ... to an ambitious venture that conjoined the passions of an NBA star, a Liberty ... Liberty community. These shoes will save lives from the rampant infections transmitted through the ...
(Date:8/18/2017)... New York, NY (PRWEB) , ... August 18, ... ... summer’s edition of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and ... today’s resources available for individuals with hearing impairments and shares the latest innovations ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning services to communities in east Texas, is launching a regional ... Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Aug. 2, 2017 CaryRx, a next-generation full-service pharmacy, ... service for patients in the Washington D.C. ... pharmacy by providing delivery of medications through the convenience of ... delivery or delivered within one hour to any location in ... to bring this invaluable service to Washington D.C. ...
(Date:7/31/2017)... 31, 2017 7D Surgical, developer of ground breaking ... the 7D Surgical System to support its strategic sales plan ... and Virginia.  7D Surgical has entered into an ... the premier medical facilities within those markets. ... Spartan ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
Breaking Medicine Technology: